Consultant-led education

Case study 2: 68-year-old female

Case study 2 follows the story of a 68-year-old female diagnosed with JAK-2 positive myelofibrosis and shows how regular assessment and monitoring prompted initiation of Defitelio® until resolution of VOD signs and symptoms.


Case studies Diagnosis and severity grading Risk assessment and monitoring Treatment


Adverse events should be reported. Reporting forms and information for the UK can be found at:

For Ireland, reporting forms and information can be found at:

Adverse events should also be reported to Jazz Pharmaceuticals at:

Defitelio® is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.